Patient Decision Aids Linked to Improved Perception of Medical Knowledge in Cancer Survivors
the Cancer Therapy Advisor take:
Patients from a patient decision aid (P-DA) trial reported increased knowledge and decision-making confidence compared to those with usual care alone, according to an article published online in the journal Cancer.
Patients with early-stage thyroid cancer at a Canadian tertiary/quaternary care center were contacted 15 to 23 months after randomization and radioactive iodine (RAI) decision-making to examine long-term outcomes.
Of the original 74 patients, 70 (95%) of them enrolled in follow-up at a mean of 17.1 months after randomization.
Results showed patients who used P-DA reported being significantly more informed about the treatment choice, aware of their options, knowledgeable about treatment benefits, and knowledgeable about risks and side effects associated with treatment (P=0.008, P =0.009, P =0.020, and P=0.001, respectively).
No significant differences were observed between the two groups in regards to decision satisfaction (P=0.142), decision regret (P=0 .199), cancer-related worry (P=0 .645), mood (P=0.211), or physician trust (P=0.764).
Patients from a patient decision aid trial reported increased knowledge and decision-making confidence.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma